Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus

Abstract

Peripheral T cell apoptosis is upregulated in active SLE, in parallel with high expression of both membrane-bound and soluble (s) Fas. Previous studies postulated that sFas down-regulates apoptosis in vitro through its blockade of the Fas-L of cytotoxic cells. We have investigated the extent of apoptosis and sFas levels in 14 patients with active (group A) and 11 with inactive SLE (group B). Fas was predominantly expressed by CD3⁺ cells from group A, whose increased serological levels of sFas were linearly correlated with the TUNEL positive cell population, whereas low titers paralleled a mild level of apoptosis in group B. This association was also investigated by measuring the effect of sFas on both cell proliferation and caspase activation. We found that incubation with sFas greatly suppressed proliferation of CD3⁺ cells, especially in group B, and in control cells from healthy donors whose content of CPP32 active products was significantly increased. We postulate that sFas promotes a pro-apoptogen effect, which would explain the high susceptibility to apoptosis in active lupus, and that the apoptosis program itself includes release of sFas to spread the death signal.

Keywords

apoptosis caspases SLE soluble Fas TUNEL

Get full access to this article

View all access options for this article.

References

Emlen W , Niebur JA , Adera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus . J Immunol 1994; 152: 3685-3692 .

Mysler E , Bini P , Drappa J et al. The apoptosis-1=Fas protein in human systemic lupus erythematosus . J Clin Invest 1994; 93: 1029-1034 .

Amasaki Y , Kobayashi S , Takeda T et al. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia . Clin Exp Immunol 1995; 99: 245-250 .

Courtney PA , Crockard AD , Williamson K et al. Lymphocyte apoptosis in systemic lupus erythematosus: relationship with Fas expression, serum soluble Fas and disease activity . Lupus 1999; 8: 508-513 .

van Lopik T , Bijl M , Hart M et al. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse . J Rheumatol 1999; 26: 60-67 .

Al-Maini MH , Mountz JD , Al-Mohri HA et al. Serum levels of soluble Fas correlate with indices of organ damage in systemic lupus erythematosus . Lupus 2000; 9: 132-139 .

Cheng J , Zhou T , Liu C et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule . Science 1994; 263: 1759-1762 .

Nozawa K , Kayagaki N , Tokano Y et al. Soluble Fas (Apo-1, CD95) and soluble Fas ligand in rheumatic diseases . Arthritis Rheum 1997; 40: 1126-1129 .

Hosaka N , Oyazu N , Kaplan MH et al. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons . J Infect Dis 1998; 178: 1030-1039 .

10.

Boylan MT , Crockard AD , McDonnell GV et al. Serum and cerebrospinal fluid soluble Fas levels in clinical subgroup of multiple sclerosis . Immunol Lett 2001; 78: 183-189 .

11.

Kuwano K , Hagimoto N , Kawasaki M et al. Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis . Int Arch Allergy Immunol 2000; 122: 209-215 .

12.

Mountz JD , Wu J , Cheng J , Zhou T. Autoimmune disease. A problem of defective apoptosis . Arthritis Rheum 1994; 37: 1415-1420 .

13.

Lorenz HM , Grünke M , Hieronymus T et al. In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases . Arthritis Rheum 1997; 40: 306-317 .

14.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1271-1277 .

15.

Bombardieri C , Gladman DD , Urowitz MB et al. Derivation of SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE . Arthritis Rheum 1992; 35: 630-640 .

16.

Silvestris F , Grinello D , Del Prete A et al. Anti-Fas (CD95=Apo-I) autoantibodies and soluble Fas levels concur in T cell depletion in HIV-1 infection . AIDS Res Hum Retrovirus 2001; 17: 603-610 .

17.

Silvestris F , Cafforio P , Frassanito MA et al. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis . AIDS 1996; 10: 131-141 .

18.

Burlingame RW , Boey ML , Starkebaum G , Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus . J Clin Invest 1994; 94: 184-192 .

19.

Al-Janadi M , Al-Balla S , Al-Dalaan A , Radiuddin S. Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases . J Clin Immunol 1993; 13: 58-67 .

20.

Dean GS , Tyrrell-Price J , Crawley E , Isenberg D. Cytokines and systemic lupus erythematosus . Ann Rheum Dis 2000; 529: 243-251 .

21.

Tokano Y , Miyake S , Kayagaki N et al. Soluble Fas molecule in the serum of patients with systemic lupus erythematosus . J Clin Immunol 1996; 16: 261-265 .

22.

Jodo S , Kobayashi S , Kayagaki N et al. Serum levels of soluble Fas=Apo-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases . Clin Exp Immunol 1997; 107: 89-95 .

23.

Suda T , Hashimoto H , Tanaka M et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing . J Exp Med 1997; 186: 2045-2050 .

24.

Knipping E , Krammer PH , Onel KB et al. Levels of soluble Fas= APO-1=CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis . Arthritis Rheum 1995; 38: 1735-1737 .

25.

Silvestris F , Cafforio P , Tucci M et al. VEINCTR-N, an immunogenic epitope of Fas (CD95=Apo-I), and soluble Fas enhance T cell apoptosis in vitro. II. Functional analysis and possible implications in HIV-1 disease . Mol Med 2000; 6: 509-526 .

26.

Siegel RM , Frederiksen JK , Zacharias DA et al. Fas pre-association required for apoptosis signaling and dominant inhibition by pathogenic mutations . Science 2000; 288: 2354-2357 .

27.

Boldin MP , Mett IL , Varfolomeev EE et al. Self-association of the ‘death domain’ of the p55 tumor necrosis factor (TNF) receptor and Fas=APO-1 prompts signaling for TNF and Fas=APO-1 effects . J Biol Chem 1995; 270: 387-391 .

28.

Chan FK , Chun HJ , Zheng L et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling . Science 2000; 288: 2351-2354 .

29.

Shoshan Y , Shapira I , Toubi E et al. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells . J Immunol 2001; 167: 5963-5969 .

30.

Ishizuya-Oka A , Li Q , Amano T et al. Requirement for matrix metalloproteinase stromelysin-3 in cell migration and apoptosis during tissue remodeling in xenopus laevis . J Cell Biol 2000; 150: 1177-1188 .

31.

Keyszer G , Lambiri I , Nagel R et al. Circulating levels of matrix metalloproteinase MMP-3 and MMP-1, tissue inhibitor of metalloproteinase 1 (TIMP-1), and MMP-1=TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers . J Rheumatol 1999; 26: 251-258 .

32.

Kotajima L , Aotsuka S , Fujimani M et al. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis . Clin Exp Rheumatol 1998; 16: 409-415 .